ArticleEuropean journal of nuclear medicine and molecular imaging2026
Diagnostic performance of [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts.Cancer cell · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo evaluate the diagnostic efficacy of a novel FAP-targeted tracer, [¹⁸F]F-FAPI-FUSCC-07, for solitary pulmonary nodules (SPNs) and to develop a reliable prediction model by integrating PET functional parameters with CT morphological features.
methodsOne hundred and thirty-seven patients with SPNs who underwent both [¹⁸F]F-FAPI-FUSCC-07 and [¹⁸F]F-FDG PET/CT were retrospectively enrolled in this study. Diagnostic performance of semi-quantitative parameters (SUVmax and TBR) for both tracers was evaluated and compared using ROC analysis. A multivariate logistic regression model was constructed in a training cohort (n = 100) and validated in an independent cohort (n = 37).
resultsBoth [¹⁸F]F-FAPI-FUSCC-07 and [¹⁸F]F-FDG PET/CT were able to discriminate between benign and malignant SPNs effectively. Compared with [¹⁸F]F-FDG PET/CT, [¹⁸F]F-FAPI-FUSCC-07 PET/CT demonstrated significantly higher diagnostic accuracy (AUC for TBR of both tracers: 0.801 vs. 0.677, p < 0.05). To better leverage the advantages of [¹⁸F]F-FAPI-FUSCC-07 PET/CT, a diagnostic model combining FAPI uptake and CT morphological features was constructed using logistic regression. The model was formulated as P = 1 / (1 + e^(-x)), where P represents the probability of malignancy, x = -1.223 + 0.502 × TBRFAPI + 1.959 × lobulation. The diagnostic model achieved superior performance with an AUC of 0.866. In the validation set, the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of the model were 87.50%, 69.23%, 81.08%, 84.00%, and 75.00%, respectively. Exploratory analysis revealed significantly lower [¹⁸F]F-FAPI-FUSCC-07 uptake in invasive mucinous adenocarcinoma than in other subtypes.
conclusion[¹⁸F]F-FAPI-FUSCC-07 PET/CT is a superior imaging tool for discriminating benign from malignant SPNs compared to [¹⁸F]F-FDG PET/CT. A prediction model combining its functional parameters with CT morphological features achieved satisfactory discriminatory ability (AUC: 0.866) in the training set and maintained good accuracy (81.08%) in an independent validation set, providing a promising non-invasive diagnostic strategy that warrants further validation in prospective studies.
Indexed as
Identifiers
41699281What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.